Cost‐effective prostate cancer detection. Reduction of low‐yield biopsies

Background. In hopes of limiting low‐yield prostate biopsies, results of digital rectal examination (DRE), transrectal ultrasound (TRUS), prostate specific antigen (PSA) and age‐related PSA values, gland‐volume‐adjusted PSA levels, and longitudinal PSA changes were analyzed to identify their cost‐effectiveness as prognostic indicators in screening, biopsy, and follow‐up of patients with prostate cancer.

[1]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[2]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[3]  C. Metz.  ROC Methodology in Radiologic Imaging , 1986, Investigative radiology.

[4]  A. Pantuck,et al.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.

[5]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[6]  R. Kane,et al.  Prostate‐specific antigen lewels in 1695 men without evidence of prostate cancer: Findings of the American cancer society national prostate cancer detection project , 2010, Cancer.

[7]  R. Vessella,et al.  Screening for prostatic carcinoma with prostate specific antigen: results of the second year. , 1993, The Journal of urology.

[8]  W F Dähnert,et al.  Determination of prostate volume with transrectal US for cancer screening. , 1992, Radiology.

[9]  R. Kane,et al.  Characteristics of prostate cancers detected in a multimodality early detection program , 1993 .

[10]  R. Vessella,et al.  Screening for prostatic carcinoma with prostate specific antigen. , 1992, The Journal of urology.

[11]  J Drago,et al.  The American cancer society national prostate cancer detection project. Findings on the detection of early prostate cancer in 2425 men , 1991, Cancer.

[12]  R. Kane,et al.  Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age‐referenced PSA, PSA density, and PSA change , 1994, Cancer.

[13]  T. Egglin,et al.  Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques. , 1991, Radiology.

[14]  M. Terris,et al.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. , 1989, The Journal of urology.

[15]  T. Egglin,et al.  Determination of prostate volume with transrectal US for cancer screening. Part I. Comparison with prostate-specific antigen assays. , 1991, Radiology.

[16]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[17]  S G Pauker,et al.  Screening for prostate cancer. A decision analytic view. , 1994, JAMA.

[18]  R. Kane,et al.  The relationship of prostate‐specific antigen to digital rectal examination and transrectal ultrasonography: Findings of the American cancer society national prostate cancer detection project , 2010, Cancer.

[19]  Curtis Mettlin,et al.  Defining and updating the american cancer society guidelines for the cancer‐related checkup: Prostate and endometrial cancers , 1993, CA: a cancer journal for clinicians.

[20]  A. Goodman,et al.  The benefit and cost of prostate cancer early detection , 1993, CA: a cancer journal for clinicians.

[21]  D. Siders,et al.  Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer , 1992, Cancer.